Tardive akathisia: An analysis of clinical features and response to open therapeutic trials
Identifieur interne : 006427 ( Main/Exploration ); précédent : 006426; suivant : 006428Tardive akathisia: An analysis of clinical features and response to open therapeutic trials
Auteurs : Burke [États-Unis] ; Un Jung Kang [États-Unis] ; Joseph Jankovic [États-Unis] ; Lucinda G. Miller [États-Unis] ; Stanley Fahn [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1989.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Akathisia, Drug-Induced, Antipsychotic Agents (adverse effects), Brain (drug effects), Disability Evaluation, Dopamine Antagonists, Dopamine antagonists, Drug Therapy, Combination, Dyskinesia, Drug-Induced (drug therapy), Female, Humans, Male, Middle Aged, Motor Skills (drug effects), Prognosis, Psychomotor Agitation (drug therapy), Receptors, Dopamine (drug effects), Retrospective Studies, Stereotyped Behavior (drug effects), Tardive akathisia.
- MESH :
- chemical , adverse effects : Antipsychotic Agents.
- drug effects : Brain, Motor Skills, Receptors, Dopamine, Stereotyped Behavior.
- drug therapy : Dyskinesia, Drug-Induced, Psychomotor Agitation.
- Adult, Aged, Aged, 80 and over, Akathisia, Drug-Induced, Disability Evaluation, Dopamine Antagonists, Drug Therapy, Combination, Female, Humans, Male, Middle Aged, Prognosis, Retrospective Studies.
Abstract
In recent years, there has been increasing recognition that akathisia occurs not only as an acute, self‐limited complication of dopamine (DA) antagonist treatment, but also as a persistent form, called tardive akathisia. We present a retrospective analysis of clinical features and therapeutic trials in 52 cases of this disorder. Although most patients developed this disorder after years of DA antagonist treatment (mean = 4.5 years), a significant proportion (34%) developed it within 1 year. The characteristic motor features included frequent, complex stereotyped movements. The legs were most frequently involved, showing marching in place and crossing/uncrossing. Trunk rocking, respiratory grunting and moaning, and complex hand movements such as face rubbing or scratching also occurred. In the 26 patients who were able to discontinue DA antagonists, akathisia persisted for years (mean = 2.7 years, range of 0.3–7 years) until abatement of symptoms or last follow‐up. Younger patients were more likely to have remission or therapeutic suppression of akathisia at follow‐up. In our experience, the catecholamine‐depleting drugs reserpine and tetrabenazine were the most effective agents for suppressing symptoms, producing improvement in 87 and 58% of patients treated, respectively. However, improvement was limited in many patients, and at last follow‐up only 33% of patients had complete abatement of their symptoms. In conclusion, tardive akathisia is a particularly disabling form of tardive dyskinesia, frequently persistent for years and often resistant to therapy.
Url:
DOI: 10.1002/mds.870040208
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000335
- to stream Istex, to step Curation: 000335
- to stream Istex, to step Checkpoint: 004457
- to stream PubMed, to step Corpus: 004F93
- to stream PubMed, to step Curation: 004F93
- to stream PubMed, to step Checkpoint: 004F61
- to stream Ncbi, to step Merge: 004252
- to stream Ncbi, to step Curation: 004252
- to stream Ncbi, to step Checkpoint: 004252
- to stream Main, to step Merge: 009780
- to stream Main, to step Curation: 006427
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Tardive akathisia: An analysis of clinical features and response to open therapeutic trials</title><author><name sortKey="Burke" sort="Burke" uniqKey="Burke" last="Burke">Burke</name></author><author><name sortKey="Kang, Un Jung" sort="Kang, Un Jung" uniqKey="Kang U" first="Un Jung" last="Kang">Un Jung Kang</name></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation><country>États-Unis</country><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Miller, Lucinda G" sort="Miller, Lucinda G" uniqKey="Miller L" first="Lucinda G." last="Miller">Lucinda G. Miller</name></author><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:0A341B5FFBDCB794AEDE1C89451D2D5A7D1134E8</idno><date when="1989" year="1989">1989</date><idno type="doi">10.1002/mds.870040208</idno><idno type="url">https://api.istex.fr/document/0A341B5FFBDCB794AEDE1C89451D2D5A7D1134E8/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">000335</idno><idno type="wicri:Area/Istex/Curation">000335</idno><idno type="wicri:Area/Istex/Checkpoint">004457</idno><idno type="wicri:doubleKey">0885-3185:1989:Burke:tardive:akathisia:an</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:2567492</idno><idno type="wicri:Area/PubMed/Corpus">004F93</idno><idno type="wicri:Area/PubMed/Curation">004F93</idno><idno type="wicri:Area/PubMed/Checkpoint">004F61</idno><idno type="wicri:Area/Ncbi/Merge">004252</idno><idno type="wicri:Area/Ncbi/Curation">004252</idno><idno type="wicri:Area/Ncbi/Checkpoint">004252</idno><idno type="wicri:doubleKey">0885-3185:1989:Burke R:tardive:akathisia:an</idno><idno type="wicri:Area/Main/Merge">009780</idno><idno type="wicri:Area/Main/Curation">006427</idno><idno type="wicri:Area/Main/Exploration">006427</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Tardive akathisia: An analysis of clinical features and response to open therapeutic trials</title><author><name sortKey="Burke" sort="Burke" uniqKey="Burke" last="Burke">Burke</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Neurology, College of Physicians and Surgeons, Columbia University</wicri:cityArea></affiliation></author><author><name sortKey="Kang, Un Jung" sort="Kang, Un Jung" uniqKey="Kang U" first="Un Jung" last="Kang">Un Jung Kang</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Neurology, College of Physicians and Surgeons, Columbia University</wicri:cityArea></affiliation><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Laboratory of Molecular Neurobiology, Burke Rehabilitation Center, White Plains</wicri:cityArea></affiliation></author><author><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName><placeName><settlement type="city">Houston</settlement><region type="state">Texas</region></placeName><orgName type="university" n="3">Baylor College of Medicine</orgName></affiliation></author><author><name sortKey="Miller, Lucinda G" sort="Miller, Lucinda G" uniqKey="Miller L" first="Lucinda G." last="Miller">Lucinda G. Miller</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author><author><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><placeName><region type="state">État de New York</region></placeName><wicri:cityArea>Department of Neurology, College of Physicians and Surgeons, Columbia University</wicri:cityArea></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1989">1989</date><biblScope unit="vol">4</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="157">157</biblScope><biblScope unit="page" to="175">175</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">0A341B5FFBDCB794AEDE1C89451D2D5A7D1134E8</idno><idno type="DOI">10.1002/mds.870040208</idno><idno type="ArticleID">MDS870040208</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Akathisia, Drug-Induced</term><term>Antipsychotic Agents (adverse effects)</term><term>Brain (drug effects)</term><term>Disability Evaluation</term><term>Dopamine Antagonists</term><term>Dopamine antagonists</term><term>Drug Therapy, Combination</term><term>Dyskinesia, Drug-Induced (drug therapy)</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Motor Skills (drug effects)</term><term>Prognosis</term><term>Psychomotor Agitation (drug therapy)</term><term>Receptors, Dopamine (drug effects)</term><term>Retrospective Studies</term><term>Stereotyped Behavior (drug effects)</term><term>Tardive akathisia</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term><term>Motor Skills</term><term>Receptors, Dopamine</term><term>Stereotyped Behavior</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Dyskinesia, Drug-Induced</term><term>Psychomotor Agitation</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Akathisia, Drug-Induced</term><term>Disability Evaluation</term><term>Dopamine Antagonists</term><term>Drug Therapy, Combination</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Prognosis</term><term>Retrospective Studies</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In recent years, there has been increasing recognition that akathisia occurs not only as an acute, self‐limited complication of dopamine (DA) antagonist treatment, but also as a persistent form, called tardive akathisia. We present a retrospective analysis of clinical features and therapeutic trials in 52 cases of this disorder. Although most patients developed this disorder after years of DA antagonist treatment (mean = 4.5 years), a significant proportion (34%) developed it within 1 year. The characteristic motor features included frequent, complex stereotyped movements. The legs were most frequently involved, showing marching in place and crossing/uncrossing. Trunk rocking, respiratory grunting and moaning, and complex hand movements such as face rubbing or scratching also occurred. In the 26 patients who were able to discontinue DA antagonists, akathisia persisted for years (mean = 2.7 years, range of 0.3–7 years) until abatement of symptoms or last follow‐up. Younger patients were more likely to have remission or therapeutic suppression of akathisia at follow‐up. In our experience, the catecholamine‐depleting drugs reserpine and tetrabenazine were the most effective agents for suppressing symptoms, producing improvement in 87 and 58% of patients treated, respectively. However, improvement was limited in many patients, and at last follow‐up only 33% of patients had complete abatement of their symptoms. In conclusion, tardive akathisia is a particularly disabling form of tardive dyskinesia, frequently persistent for years and often resistant to therapy.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li><li>État de New York</li></region><settlement><li>Houston</li></settlement><orgName><li>Baylor College of Medicine</li></orgName></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Burke" sort="Burke" uniqKey="Burke" last="Burke">Burke</name></region><name sortKey="Fahn, Stanley" sort="Fahn, Stanley" uniqKey="Fahn S" first="Stanley" last="Fahn">Stanley Fahn</name><name sortKey="Jankovic, Joseph" sort="Jankovic, Joseph" uniqKey="Jankovic J" first="Joseph" last="Jankovic">Joseph Jankovic</name><name sortKey="Kang, Un Jung" sort="Kang, Un Jung" uniqKey="Kang U" first="Un Jung" last="Kang">Un Jung Kang</name><name sortKey="Kang, Un Jung" sort="Kang, Un Jung" uniqKey="Kang U" first="Un Jung" last="Kang">Un Jung Kang</name><name sortKey="Miller, Lucinda G" sort="Miller, Lucinda G" uniqKey="Miller L" first="Lucinda G." last="Miller">Lucinda G. Miller</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 006427 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 006427 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:0A341B5FFBDCB794AEDE1C89451D2D5A7D1134E8
|texte= Tardive akathisia: An analysis of clinical features and response to open therapeutic trials
}}
| This area was generated with Dilib version V0.6.23. |  |